Compare Organon & Co. Common Stock (OGN) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Western Union Co — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Western Union Co trades at $6.05 (market cap $1.90B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Western Union Co pays the higher dividend (15.41%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Western Union Co for 96 Days on average.
| OGN | WU | |
|---|---|---|
Market Cap | $3.62B | $1.90B |
Volume | 2,892,999 | 6,506,793 |
Sector | Health | Financials |
52-Week High | $13.81 | $10.28 |
52-Week Low | $5.70 | $5.90 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $11.04B | $1.81B |
Dividend Yield | 0.58% | 15.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Western Union (WU) trades at $6.05, down 0.98% on the day and near its 52-week low of $6.00. The stock shows bearish technical signals with recent earnings misses in Q1 and Q2 2026. Fundamentally, WU maintains strong profitability with a 9.79% net margin and attractive valuation metrics including a P/E of 4.92. The company's $200 million cost-cutting initiative and Intermex acquisition aim to drive future growth despite revenue declines from $4.5B in 2022 to $4.05B in 2025.
WU presents a value opportunity with deep undervaluation but faces execution risks. The stock trades below analyst consensus target of $6.71, offering 11% upside potential. However, declining revenue trends, integration challenges from the Intermex acquisition, and competitive pressures in money transfer services create headwinds. Investor sentiment remains cautious with only 12% buy ratings from analysts, reflecting concerns about the company's digital transition and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
